Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial

Powell, M.A.; Bjørge, Line; Willmott, Lyndsay; Novák, Z.; Black, D.; Gilbert, L.; Sharma, S.; Valabrega, G.; M. Landrum, Lisa; Gropp‐Meier, Martina; Stuckey, A.; Boere, Ingrid; A. Gold, Michael; Segev, Yakir; Gill, S.E.; Gennigens, Christine; Sebastianelli, Alexandra; S. Shahin, Mark; Pothuri, Bhavana; Monk, B.J.; Buscema, Joseph; Coleman, R.L.; Slomovitz, B.M.; L. Ring, Kari; Herzog, T.J.; Marco Balas, Morad; Grimshaw, M.; Stevens, S.; W. Lai, Dominic; K. McCourt, Carolyn; Mirza, MR

doi:10.1016/j.annonc.2024.05.546

Public

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial

Published in Annals of Oncology • Jun 10, 2024

Authors:

M.A. Powell

Line Bjørge

Lyndsay Willmott

Abstract

BACKGROUND: Part 1 of the RUBY trial (NCT03981796) evaluated dostarlimab plus carboplatin-paclitaxel compared with placebo plus carboplatin-paclitaxel in patients with primary advanced or recurrent endometrial cancer (EC). At the first interim analysis, the trial met one of its dual primary endpoint...

Subject

Carboplatin

Medicine

Paclitaxel

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!